Most notably, in this clinical context, Mps1 inhibition has been shown to be well tolerated in patients (Hilton et al. 2022) and has recently received FDA fast-track designation for the treatment of adult patients with ER + /HER2 − advanced breast cancer after progression to CDK4/6 inhibitors and hormone therapy. This evidence concerns the gene CDK4 and breast carcinoma.